Retatrutide (5 mg vial) dosing protocol

Quick start

Retatrutide is an investigational triple agonist peptide (GLP‑1, GIP, and glucagon receptors) studied for obesity and type 2 diabetes. Phase 2 trials reported substantial weight loss at higher weekly doses. This page is educational and summarises typical weekly subcutaneous titration patterns seen in public trial materials and community dosing guides.

Reconstitution (example): add 1.0 mL bacteriostatic water to a 5 mg lyophilised vial → about 5.0 mg/mL.
Typical weekly range (trials / guides): about 2–8 mg/week with gradual escalation over 8–12+ weeks (some advanced schedules go higher; tolerability matters).
U‑100 insulin syringe “units”: at 5.0 mg/mL, 1 unit = 0.01 mL ≈ 50 mcg.
Storage: lyophilised: −20 °C (or as supplier states); after reconstitution: 2–8 °C, protect from light, commonly used within ~4 weeks (follow your supplier COA / insert).

Standard / gradual titration (1.0 mL diluent → ~5.0 mg/mL)

Phase	Weekly dose	Syringe units (mL)	Vials per dose
Weeks 1–4	2 mg	40 units (0.40 mL)	1× 5 mg vial
Weeks 5–8	4 mg	80 units (0.80 mL)	1× 5 mg vial
Weeks 9–12	6 mg	120 units (1.20 mL)	2× 5 mg vials*
Weeks 13+	8 mg	160 units (1.60 mL)	2× 5 mg vials*

*For doses >5 mg from a 5 mg/mL solution, you prepare enough total mass across multiple 5 mg vials (each reconstituted) and withdraw the required volume. Volumes >1.0 mL are sometimes split into two SC injections at different sites the same day.

Frequency: once weekly, subcutaneous, same weekday when possible.

Reconstitution steps (general)

Withdraw 1.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; minimise foaming.
Swirl gently until dissolved (avoid violent shaking).
Label with date; store refrigerated 2–8 °C, protected from light.
Use within the stability window your supplier documents (often ~4 weeks after reconstitution).

“Aggressive” example (still titrated; higher maintenance)

Higher weekly targets (e.g. 12 mg/week in some phase 2 contexts) require more vials per week and careful GI tolerability management. If you are not a qualified professional running a lawful trial, do not treat these numbers as a personal prescription.

Supplies (rough planning)

5 mg vials: count depends on dose and weeks on therapy (higher mg/week ⇒ more vials).
U‑100 1 mL syringes: typically 1–3/week depending on dose and whether large volumes are split.
Bacteriostatic water: about 1.0 mL per 5 mg vial you reconstitute, plus a small dead‑space buffer.

Mechanism (high level)

GLP‑1 / GIP signalling supports satiety and glucose‑dependent insulin dynamics; adding glucagon receptor agonism is hypothesised to increase energy expenditure and support fat oxidation beyond GLP‑1/GIP alone. Retatrutide is engineered for a long circulation profile suitable for weekly dosing in trials.

Safety / tolerability (trial themes)

Common class effects include nausea, vomiting, diarrhoea, constipation, often dose‑related and improved by slower titration. Hypoglycaemia patterns depend on population (e.g. background glucose‑lowering drugs). Discuss risks with a licensed clinician where applicable.

Recommended supplier (third‑party)

For research‑grade materials with batch documentation, many teams compare suppliers such as Crystal Peptides. reta.cc is informational only and does not sell peptides.

Important

Retatrutide is not approved for routine medical use in many jurisdictions; availability outside lawful research channels varies. This site does not encourage misuse. All dosing discussion is educational and may be incomplete or outdated.